Here’s what you should know.
1. Boston Scientific closed the transaction on Nov. 22, 2016.
2. Boston Scientific will fold in EndoChoice’s portfolio into its product line.
3. Boston Scientific said it would evaluate its “strategic options” for the Full Spectrum Endoscopy colonoscope. It’ll announce any plans it has for the device by the year’s end.
4. Boston Scientific isn’t projecting this deal to affect its earnings this year, and it expects profitability in the following years.
More articles on gastroenterology/endoscopy:
Outreach to cirrhosis patients increases likelihood of liver cancer screening: 3 study insights
GI leader to know: Dr. Muhammad Ali of Gastroenterology Consultants of San Antonio
AGA urges members to petition Congress over FY17 funding bill: 4 thoughts
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.